血清miR-520e、miR-146a表达与老年HBV相关肝癌患者临床病理参数及预后的关系
DOI:
作者:
作者单位:

作者简介:

通讯作者:

基金项目:

四川省干部保健科研课题(川干研2021-1301)


Relationship between serum miR-520e, miR-146a and clinicopathological parameters, prognosis in elderly patients with HBV-related hepatocellular carcinoma
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    目的 探讨血清miR-520e、miR-146a表达与老年乙型肝炎病毒(HBV)相关肝癌患者临床病理参数及预后的关系。方法 将2018年2月—2021年2月本院收治的HBV相关肝细胞癌患者95例设为观察组,将同期HBV患者100例设为对照组,采用实时聚合酶链反应法(RT-PCR)检测两组血清中miR-520e和miR-146a水平。比较两组血清中miR-520e和miR-146a水平的差异,以及观察组中不同病理特征患者血清中miR-520e和miR-146a水平的差异,绘制不同miR-520e和miR-146a水平肝癌患者的1年无进展生存期生存曲线。结果 观察组患者血清miR-520e、miR-146a水平均低于对照组患者(P<0.05);HCC患者中,病灶大小≥3 cm、有癌栓、伴淋巴结转移、TNM分期 Ⅲ~Ⅳ期的患者血清miR-520e水平明显低于病灶大小<3 cm、无癌栓、不伴淋巴结转移、TNM分期 Ⅰ~Ⅱ期的患者(P<0.05);HCC患者中,病灶大小≥3 cm、有癌栓、伴淋巴结转移、TNM分期 Ⅲ~Ⅳ期的患者血清miR-146a水平明显低于病灶大小<3 cm、无癌栓、不伴淋巴结转移、TNM分期 Ⅰ~Ⅱ期的患者(P<0.05);将观察组患者中miR-520e水平低于平均值患者分为低miR-520e表达组,高于平均值患者分为高miR-520e表达组;将观察组患者中miR-146a水平低于平均值患者分为低miR-146a表达组,高于平均值患者分为高miR-146a表达组。曲线分析结果显示,miR-520e和miR-146a高表达者1年内无进展生存期情况均明显优于低表达者(P<0.05)。结论 HBV相关肝细胞癌患者中miR-520e和miR-146a血清水平显著低于HBV患者,且不同miR-520e和miR-146a血清水平的HBV相关肝细胞癌患者之间临床病理特征与预后存在显著差异

    Abstract:

    Objective To explore the relationship between serum miR-520e, miR-146a and clinicopathological parameters, prognosis in elderly patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Methods A total of 95 patients with HBV-related HCC and 100 patients with HBV in the hospital were enrolled as observation group and control group from February 2018 to February 2021. The levels of serum miR-520e and miR-146a in both groups were detected by real-time polymerase chain reaction (RT-PCR). The differences in the two indexes between the two groups and among patients with different pathological characteristics in observation group were compared. The 1-year progression-free survival curves in HCC patients with different levels of miR-520e and miR-146a were drawn. Results The levels of serum miR-520e and miR-146a in observation group were lower than those in control group (P<0.05). In HCC patients, levels of serum miR-520e and miR-146a in patients with lesion ≥3cm, cancer thrombus, lymph node metastasis and TNM staging at stage III-IV were significantly lower than those with lesion <3cm, without cancer thrombus or lymph node metastasis, and with TNM staging at stage Ⅰ-Ⅱ (P<0.05). In observation group, patients with miR-520e level lower or higher than the average were enrolled as low-expression miR-520e group and high-expression miR-520e group. In observation group, patients with miR-146a level lower or higher than the average were enrolled as low-expression miR-146a group and high-expression miR-146a group. The results of curves analysis showed that 1-year progression-free survival in patients with high expressions of miR-520e and miR-146a was significantly better than that with low expressions (P<0.05). Conclusion The levels of serum miR-520e and miR-146a in patients with HBV-related HCC are significantly lower than those in HBV patients. In patients with HBV-related HCC, there are significant differences in clinicopathological characteristics and prognosis among patients with different levels of serum miR-520e and miR-146a

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2024-09-18
您是第位访问者
网站版权所有:《西部医学》编辑部     蜀ICP备18038379号-4
地址:四川省成都市武侯区小天竺街75号财富国际18F-1号    邮政编码:610041
电话:028-85570072/85588403 本网站支持 IPv6    E-mail:xbyxqk@163.com
技术支持:北京勤云科技发展有限公司